DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20190335

Predictivity of inflammatory cell counts in early diagnosis of hydatidiform mole

Hüseyin Avni Eroğlu, Yasemen Adalı

Abstract


Background: Hydatidiform mole (HM) is the most frequently encountered disease among gestational trophoblastic diseases. HM can invade myometrium and result in hysterectomy and because of the absence of any predictive method, the disease  can  be lately diagnosed in the periphery. Author aimed to evaluate predictive value of  the inflammatory cell counts in molar pregnancies in this study.

Methods: Nineteen (19) cases with histopathologic HM diagnosis and 19 cases of control group with pregnancy termination or abortion material reached to a university hospital's pathology department on the same day were included in the study. The data on the same day or the day before the operation was used as the hemogram data.

Results: The mean age of the cases were 33.84±8.477. The mean of neutrophil, lymphocyte, monocyte, basophil and eosinophil numbers of the HM group and control group were compared in the 95% confidence interval with the independent t test. No statistical significance was observed in any of the inflammatory cell means  (p>0.05). The ratio of lymphocyte means was statistically significant (p=0.006).

Conclusions: In this study, author assessed whether the inflammatory cell counts were a predictive in detecting HM. The statistically significant results that author founded in the means of lymphocyte, suggests that this finding may be predictive of early diagnosis. They concluded that this result can be routinely used after the confirmation of the results in larger series of cases.


Keywords


Hydatidiform mole, Inflammatory cell, Lymphocyte, Molar pregnancy, Neutrophil

Full Text:

PDF

References


Szulman AE, Surti U. The syndromes of hydatidiform mole: I. cytogenetic and morphologic correlations. Am J Obstetrics Gynecol. 1978;131(6):665-71.

Sebire NJ, Makrydimas G, Agnantis NJ, Zagorianakou N, Rees H, Fisher RA. Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. Anticancer Res. 2003;23(2C):1723-8.

Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4(11):670-8.

Smith HO. Gestational trophoblastic disease epidemiology and trends. Clin Obstet Gynecol. 2003;46(3):541-56.

Sun SY, Amed AM, Bertini AM, Camano L. Incidence of hydatidiform mole at the paulista medical school. Rev Assoc Med Bras. 1992;38(4):217-20.

Savage P, Williams J, Wong SL, Short D, Casalboni S, Catalano K, et al. The demographics of molar pregnancies in England and Wales from 2000-2009. J Rep Med. 2010;55(7-8):341-5.

Lybol C, Thomas CM, Bulten J, Van Dijck JA, Sweep FC, Massuger LF. Increase in the incidence of gestational trophoblastic disease in The Netherlands. Gynecol Oncol. 2011;121(2):334-8.

Mourali M, Fkih C, Essoussi-Chikhaoui J, Ben AH, Binous N, Ben NZ, et al. Gestational trophoblastic disease in Tunisia. Tunisie Med. 2008;86(7):665-9.

Matsui H, Iitsuka Y, Yamazawa K, Tanaka N, Seki K, Sekiya S. Changes in the incidence of molar pregnancies: a population‐based study in Chiba Prefecture and Japan between 1974 and 2000. Human Repro. 2003;18(1):172-5.

Matsui H, Kihara M, Yamazawa K, Mitsuhashi A, Seki K, Sekiya S. Recent changes of the incidence of complete and partial mole in Chiba prefecture. Gynecol Obstetric Investigation. 2007;63(1):7-10.

Ghaemmaghami F, Ashraf‐ganjooie T. Gestational trophoblastic neoplasia. Asia‐Pacific J Clin Oncol. 2006;2(1):9-21.

Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG: Inter J Obstetrics Gynaecol. 2002;109(1):99-102.

Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstetrics Gynaecol. 2013;33(4):406-11.

Altman AD, Bentley B, Murray S, Bentley JR. Maternal age-related rates of gestational trophoblastic disease. Obstetrics Gynecol. 2008;112(2):244-50.

Harma M, Kocyigit A, Yurtseven S, Demir N. Serum levels of folate, vitamin B12 and homocysteine in complete hydatidiform mole. J Repro Med. 2004;49(4):285-8.

Berkowitz RS, Goldstein DP. Gestational trophoblastic disease. In: Berek and Hacker’s Gynecologic Oncology. 6th ed. Berek JS, Hacker NF, eds. Wolters Kluwer: NY; 2015:625-48.

Ubong IC, Uji AB, Efiok EE, Abeng EG, Felix N. A ten-years review of hydatidiform mole in university of Calabar teaching hospital Nigeria. J Obstet Gynecol. 2015;3:88-91.

Boufettal H, Coullin P, Mahdaoui S, Noun M, Hermas S, Samouh N. Complete hydatiforme mole in Morocco: epidemiological and clinical study. J Gynecol, Obstet Biol Repro. 2011;40(5):419-29.

Milani HS, Abdollahi M, Torbati S, Asbaghi T, Azargashb E. risk factors for hydatidiform mole: is husband’s job a major risk factor?. APJCP. 2017;18(10):2657.

Stafford L, McNally OM, Gibson P, Judd F. Long-term psychological morbidity, sexual functioning, and relationship outcomes in women with gestational trophoblastic disease. Inter J Gynecol Cancer. 2011;21(7):1256-63.

Ozalp SS, Oge T. Gestational trophoblastic diseases in Turkey. J Repro Med. 2013;58(1-2):67-71.

Ozalp SS, Telli E, Oge T, Tulunay G, Boran N, Turan T, et al. Multi-center analysis of gestational trophoblastic neoplasia in Turkey. Asian Pacific J Cancer Prevention: APJCP. 2014;15(8):3625-8.

Gray Cunningham F, Leveno KJ, Bloom SL, eds. Williams Obstetrics. 24th ed. McGrow-hill: NY;2014:396-405.

Gockley AA, Joseph NT, Melamed A, Sun SY, Goodwin B, Bernstein M, et al. Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. Am J Obstet Gynecol. 2016;215(3):334-e1.

Berkowitz RS, Cramer DW, Bernstein MR, Cassells S, Driscoll SG, Goldstein DP. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol. 1985;152(8):1016-20.

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531-9.

Andreasen L, Christiansen OB, Niemann I, Bolund L, Sunde L. NLRP7 or KHDC3L genes and the etiology of molar pregnancies and recurrent miscarriage. Molecular Human Repro. 2013;19(11):773-81.

Slim R, Fallahian M, Rivière JB, Zali MR. Evidence of a genetic heterogeneity of familial hydatidiform moles. Placenta. 2005;26(1):5-9.

Yang X, Zhang Z, Jia C, Li J, Yin L, Jiang S. The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole. Gynecol Oncol. 2002;85(3):438-44.

Sun SY, Melamed A, Goldstein DP, Bernstein MR, Horowitz NS, Moron AF, et al. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?. Gynecol Oncol. 2015;138(1):46-9.

Kim BW, Cho H, Kim H, Nam EJ, Kim SW, Kim S, et al. Human chorionic gonadotrophin regression rate as a predictive factor of post molar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study. Euro J Obstet Gynecol Repro Biol. 2012;160(1):100-5.

Kohorn EI, Kacinski BM, Stanley ER. Serum levels of macrophage colony-stimulating factor in trophoblastic disease. Gynecol Oncol. 2001;80(3):383-6.

Hegab HM, Schindler AE, Rizk M, Ramadan M. Evaluation of tumour markers in molar pregnancy. Arch Gynecol Obstet. 2003;268(3):151-4.

Sutoto MT. Cellular immune response levels in gestational trophoblastic tumor patients after hydatidiform mole. Inter J Gynecol Obstet. 1999;65(3):273-9.

Abide Yayla C, Özkaya E, Yenidede I, Eser A, Ergen EB, Tayyar AT, et al. Predictive value of some haematological parameters for non-invasive and invasive mole pregnancies. J Maternal-Fetal Neonatal Med. 2018;31(3):271-7.

Guzel AI, Kokanali MK, Erkilinc S, Topcu HO, Oz M, Ozgu E, et al. Predictive role of the neutrophil lymphocyte ratio for invasion with gestational trophoblastic disease. Asian Pac J Cancer Prev. 2014;15(10):4203-6.